Neurocrine Biosciences Inc (NBIX)

52.15
NASDAQ : Health Care
Prev Close 53.12
Day Low/High 52.07 / 53.78
52 Wk Low/High 37.34 / 55.38
Avg Volume 1.10M
Exchange NASDAQ
Shares Outstanding 88.22M
Market Cap 4.69B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Neurocrine Biosciences To Present At The Goldman Sachs 38th Annual Global Healthcare Conference

Live Audio Webcast Will be on June 15, 2017

Neurocrine Biosciences To Present At The Jefferies 2017 Global Healthcare Conference

Live Audio Webcast Will be on June 8, 2017

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Neurocrine Announces Phase II Results Of VMAT2 Inhibitor INGREZZA® For Treatment Of Tourette Syndrome

Study Provides Clear Path Forward for Future Pivotal Studies

AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis

- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference

Live Audio Webcast Will be on May 17, 2017

Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2017 Results

Conference Call and Webcast Scheduled for Tuesday, May 9, 2017

Neurocrine Announces INGREZZA™ Long-Term Safety And Efficacy Data To Be Presented At The 2017 American Academy Of Neurology Annual Meeting

Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Geopolitical concerns dominated market moves as banks kicked off earnings season.

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

Wall Street Closes Lower Amid Continued Global Worries

Wall Street Closes Lower Amid Continued Global Worries

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Stocks Fall as Wall Street Can't Shake Geopolitical Concerns

Stocks Fall as Wall Street Can't Shake Geopolitical Concerns

Stocks are lower on Wednesday as markets continue to grapple with geopolitical uncertainty.

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

The company's shares were up 24% ahead of market's open on an FDA approval.

Neurocrine Announces FDA Approval Of INGREZZA™ (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD) (with Multimedia)

Provides significant and rapid reduction in involuntary movements with simple once-daily dosing

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

The U.S. Food and Drug Administration granted Ingrezza a relatively clean label that does not include a black box safety warning against suicidality or depression.

Neurocrine Announces FDA Approval Of INGREZZA TM (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD)

Provides significant and rapid reduction in involuntary movements with simple once-daily dosing

AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding In Women With Uterine Fibroids

- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids

Neurocrine Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (valbenazine) For The Treatment Of Tardive Dyskinesia

- Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA

Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone

Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease

Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2016 Results

Conference Call and Webcast Scheduled for Tuesday, February 14, 2017